


New adjuvant successful in extending immunity against HIV

20 June 2020, by Lisa Newbern



Microscopic image of an HIV-infected T cell. Credit: NIAID

Researchers at the Yerkes National Primate Research Center and the Emory Vaccine Center (EVC) are first to show a new adjuvant, 3M-052, helps induce long-lasting immunity against HIV. The study results are published today in *Science Immunology*.

In this pre-[clinical study](#) that included 90 [rhesus monkeys](#), the researchers showed 3M-052, a new, synthetic small molecule that targets a specific receptor (TLR 7/8), successfully induced vaccine-specific, long-lived bone marrow plasma cells (BM-LLPCs), which are critical for durable immunity. In a striking observation, 3M-052-induced BM-LLPCs were maintained at high numbers for more than one year after vaccination. This prolonged interval is not only feasible in monitoring pre-[clinical effectiveness](#), it is also highly informative in down selecting vaccine candidates.

First author Sudhir Pai Kasturi, Ph.D., an assistant professor in the Department of Pathology and Laboratory Medicine and a research assistant

professor at Yerkes and the EVC, says, "We have known adjuvants are critical immunity-boosting supplements that help improve the effectiveness of vaccines. Until now, however, it has been unclear which class of adjuvants can promote stable and long-lived immunity in nonhuman primate models. Our study provides that information."

Co-senior author Rafi Ahmed, Ph.D., director of the Emory Vaccine Center, adds, "The key to a successful vaccine is durability of immune responses. Antibodies provide the first line of defense against pathogens, and [antibody levels](#) are maintained by the generation of long-lived plasma cells that reside in bone marrow. Our study identifies an adjuvant that is effective in generating such long-lived plasma cells in bone marrow. This finding has implications for developing successful vaccines against HIV, influenza and, especially important now, COVID-19.

More information: Sudhir Pai Kasturi et al, 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates, *Science Immunology* (2020). [DOI: 10.1126/sciimmunol.abb1025](#)

Provided by Emory University

APA citation: New adjuvant successful in extending immunity against HIV (2020, June 20) retrieved 28 April 2021 from <https://medicalxpress.com/news/2020-06-adjuvant-successful-immunity-hiv.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.